vs
Side-by-side financial comparison of Element Solutions Inc (ESI) and Hologic (HOLX). Click either name above to swap in a different company.
Hologic is the larger business by last-quarter revenue ($1.0B vs $840.0M, roughly 1.2× Element Solutions Inc). Hologic runs the higher net margin — 17.1% vs 6.7%, a 10.4% gap on every dollar of revenue. On growth, Element Solutions Inc posted the faster year-over-year revenue change (41.0% vs 2.5%). Hologic produced more free cash flow last quarter ($215.2M vs $-74.2M). Over the past eight quarters, Element Solutions Inc's revenue compounded faster (17.1% CAGR vs 1.5%).
Element Solutions Inc is an American specialty chemicals production corporation listed on the New York Stock Exchange.
Hologic, Inc. is an American medical technology company primarily focused on women's health; it sells medical devices for diagnostics, surgery, and medical imaging.
ESI vs HOLX — Head-to-Head
Income Statement — Q1 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $840.0M | $1.0B |
| Net Profit | $56.0M | $179.1M |
| Gross Margin | 38.4% | 56.0% |
| Operating Margin | 13.3% | 22.6% |
| Net Margin | 6.7% | 17.1% |
| Revenue YoY | 41.0% | 2.5% |
| Net Profit YoY | -43.0% | -10.9% |
| EPS (diluted) | $0.23 | $0.79 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $840.0M | — | ||
| Q4 25 | $676.2M | $1.0B | ||
| Q3 25 | $656.1M | $1.0B | ||
| Q2 25 | $625.2M | $1.0B | ||
| Q1 25 | $593.7M | $1.0B | ||
| Q4 24 | $624.2M | $1.0B | ||
| Q3 24 | $645.0M | $988.0M | ||
| Q2 24 | $612.7M | $1.0B |
| Q1 26 | $56.0M | — | ||
| Q4 25 | $6.2M | $179.1M | ||
| Q3 25 | $39.3M | $187.2M | ||
| Q2 25 | $47.4M | $194.9M | ||
| Q1 25 | $98.0M | $-17.4M | ||
| Q4 24 | $54.7M | $201.0M | ||
| Q3 24 | $40.3M | $178.6M | ||
| Q2 24 | $93.2M | $194.5M |
| Q1 26 | 38.4% | — | ||
| Q4 25 | 40.9% | 56.0% | ||
| Q3 25 | 42.2% | 55.6% | ||
| Q2 25 | 42.6% | 56.3% | ||
| Q1 25 | 42.2% | 37.5% | ||
| Q4 24 | 41.0% | 56.8% | ||
| Q3 24 | 41.5% | 56.4% | ||
| Q2 24 | 43.6% | 55.4% |
| Q1 26 | 13.3% | — | ||
| Q4 25 | 10.3% | 22.6% | ||
| Q3 25 | 15.4% | 22.6% | ||
| Q2 25 | 15.1% | 24.9% | ||
| Q1 25 | 13.0% | -0.7% | ||
| Q4 24 | 12.0% | 22.5% | ||
| Q3 24 | 14.7% | 23.3% | ||
| Q2 24 | 15.7% | 24.1% |
| Q1 26 | 6.7% | — | ||
| Q4 25 | 0.9% | 17.1% | ||
| Q3 25 | 6.0% | 17.8% | ||
| Q2 25 | 7.6% | 19.0% | ||
| Q1 25 | 16.5% | -1.7% | ||
| Q4 24 | 8.8% | 19.7% | ||
| Q3 24 | 6.2% | 18.1% | ||
| Q2 24 | 15.2% | 19.2% |
| Q1 26 | $0.23 | — | ||
| Q4 25 | $0.03 | $0.79 | ||
| Q3 25 | $0.16 | $0.84 | ||
| Q2 25 | $0.20 | $0.86 | ||
| Q1 25 | $0.40 | $-0.08 | ||
| Q4 24 | $0.22 | $0.87 | ||
| Q3 24 | $0.17 | $0.75 | ||
| Q2 24 | $0.39 | $0.82 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $177.3M | $2.4B |
| Total DebtLower is stronger | — | $2.5B |
| Stockholders' EquityBook value | $2.7B | $5.2B |
| Total Assets | $5.7B | $9.2B |
| Debt / EquityLower = less leverage | — | 0.48× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $177.3M | — | ||
| Q4 25 | $626.5M | $2.4B | ||
| Q3 25 | $594.3M | $2.2B | ||
| Q2 25 | $529.9M | $1.9B | ||
| Q1 25 | $499.2M | $1.6B | ||
| Q4 24 | $359.4M | $2.0B | ||
| Q3 24 | $376.0M | $2.3B | ||
| Q2 24 | $309.3M | $2.4B |
| Q1 26 | — | — | ||
| Q4 25 | $1.6B | $2.5B | ||
| Q3 25 | $1.6B | $2.5B | ||
| Q2 25 | $1.6B | $2.5B | ||
| Q1 25 | $1.6B | $2.5B | ||
| Q4 24 | $1.8B | $2.5B | ||
| Q3 24 | $1.9B | $2.5B | ||
| Q2 24 | $1.9B | $2.5B |
| Q1 26 | $2.7B | — | ||
| Q4 25 | $2.7B | $5.2B | ||
| Q3 25 | $2.7B | $5.0B | ||
| Q2 25 | $2.6B | $4.8B | ||
| Q1 25 | $2.5B | $4.6B | ||
| Q4 24 | $2.4B | $4.8B | ||
| Q3 24 | $2.4B | $5.1B | ||
| Q2 24 | $2.4B | $5.0B |
| Q1 26 | $5.7B | — | ||
| Q4 25 | $5.1B | $9.2B | ||
| Q3 25 | $5.0B | $9.0B | ||
| Q2 25 | $5.0B | $8.8B | ||
| Q1 25 | $4.8B | $8.5B | ||
| Q4 24 | $4.9B | $8.7B | ||
| Q3 24 | $5.1B | $9.2B | ||
| Q2 24 | $5.0B | $8.9B |
| Q1 26 | — | — | ||
| Q4 25 | 0.61× | 0.48× | ||
| Q3 25 | 0.61× | 0.50× | ||
| Q2 25 | 0.62× | 0.52× | ||
| Q1 25 | 0.64× | 0.55× | ||
| Q4 24 | 0.76× | 0.53× | ||
| Q3 24 | 0.78× | 0.49× | ||
| Q2 24 | 0.81× | 0.51× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $229.9M |
| Free Cash FlowOCF − Capex | $-74.2M | $215.2M |
| FCF MarginFCF / Revenue | -8.8% | 20.5% |
| Capex IntensityCapex / Revenue | 3.0% | 1.4% |
| Cash ConversionOCF / Net Profit | — | 1.28× |
| TTM Free Cash FlowTrailing 4 quarters | — | $1.0B |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | — | $229.9M | ||
| Q3 25 | $100.1M | $355.1M | ||
| Q2 25 | — | $343.3M | ||
| Q1 25 | $26.0M | $169.4M | ||
| Q4 24 | — | $189.3M | ||
| Q3 24 | $98.5M | $367.0M | ||
| Q2 24 | — | $405.8M |
| Q1 26 | $-74.2M | — | ||
| Q4 25 | — | $215.2M | ||
| Q3 25 | $83.6M | $341.4M | ||
| Q2 25 | — | $330.5M | ||
| Q1 25 | $15.0M | $153.9M | ||
| Q4 24 | — | $172.5M | ||
| Q3 24 | $85.9M | $350.6M | ||
| Q2 24 | — | $385.3M |
| Q1 26 | -8.8% | — | ||
| Q4 25 | — | 20.5% | ||
| Q3 25 | 12.7% | 32.5% | ||
| Q2 25 | — | 32.3% | ||
| Q1 25 | 2.5% | 15.3% | ||
| Q4 24 | — | 16.9% | ||
| Q3 24 | 13.3% | 35.5% | ||
| Q2 24 | — | 38.1% |
| Q1 26 | 3.0% | — | ||
| Q4 25 | 2.5% | 1.4% | ||
| Q3 25 | 2.5% | 1.3% | ||
| Q2 25 | 2.8% | 1.3% | ||
| Q1 25 | 1.9% | 1.5% | ||
| Q4 24 | 3.6% | 1.6% | ||
| Q3 24 | 2.0% | 1.7% | ||
| Q2 24 | 2.4% | 2.0% |
| Q1 26 | — | — | ||
| Q4 25 | — | 1.28× | ||
| Q3 25 | 2.55× | 1.90× | ||
| Q2 25 | — | 1.76× | ||
| Q1 25 | 0.27× | — | ||
| Q4 24 | — | 0.94× | ||
| Q3 24 | 2.44× | 2.05× | ||
| Q2 24 | — | 2.09× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ESI
| Electronics ex-Metals | $377.8M | 45% |
| Pass-through Metals | $255.7M | 30% |
| Other | $206.5M | 25% |
HOLX
| Molecular Diagnostics | $255.3M | 24% |
| Breast Imaging | $219.9M | 21% |
| Services | $216.4M | 21% |
| Capital Equipment Componentsand Software | $187.2M | 18% |
| Cytology Perinatal | $76.0M | 7% |
| Interventional Breast Solutions | $71.2M | 7% |
| Blood Screening | $8.4M | 1% |
| Other Typeof Revenue | $5.4M | 1% |
